

Serial No.: To be Assigned  
Case No.: 20991P  
Page No.: 30

REMARKS

Consideration of the application and the amendments above is respectfully requested.

In the specification, the new paragraph to be inserted on page 1, line 4, was added after the "TITLE OF THE INVENTION" paragraph on page 1, lines 1-3 and before the "SUMMARY OF INVENTION" paragraph on page 1, line 8, to provide the priority of the present application.

No new matter is being added to the above-captioned application by the submission of the Abstract of the Invention, because it is identical to that in the priority document PCT/US03/02351.


For the Examiner's convenience, a separate sheet for the Abstract of the Invention (page 128) is enclosed for inclusion with the specification of the U.S. National Phase Application being filed.

Claims 1 to 21 are pending in the application. Claims 22-31 have been cancelled. Claim 21 has been amended to incorporate the pharmaceutically active agents originally in Claims 22-25 into the claim. No new matter is added by this amendment.

Applicants respectfully contend that the application is allowable, and a favorable response from the Examiner is earnestly solicited.

Respectfully submitted,

By



Catherine D. Fitch, Reg. No. 36,502  
Attorney for Applicants

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
Tel: (732)594-4283

July 9, 2004